Peptides and GLP-1 drugs at Festival of Biologics 2026

Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website

7 organizations at Festival of Biologics 2026 present work in peptides & GLP-1: 4 drug developers, 2 suppliers and service providers and 1 academic, government or non-profit body. Between them they bring 12 presentations to the program. Most represented: AstraZeneca (6 on the program), University College Dublin (2 on the program), Ironwood Pharmaceuticals (1 on the program). 4 of them have their own page in this guide. As of Sep 26, 2026.

All 378 organizations at Festival of Biologics 2026 →

Showing 1–7 of 7 organizations

Organization	Festival of Biologics 2026 Attendance
AstraZeneca Cambridge, United Kingdom
	Talk Tue Oct 13 16:50 Optimizing recombinant protein expression workflows by leveraging automation and predictive models Ways to speed up making proteins in the lab by combining automated workflows with models that predict the best genetic code choices. Talk Tue Oct 13 17:50 Advancing Antibody Discovery Through Integrated single B-Cell Technologies How to find therapeutic antibodies by profiling individual immune B cells, and how computer predictions are combined with the laboratory work. Talk Wed Oct 14 12:30 High throughput analysis supporting cell line development CMC & Developability Chair Wed Oct 14 16:45 Chair's Remarks CMC & Developability Talk Wed Oct 14 16:50 Integrating AI/ML into Biologics Discovery: Design, Optimization, Developability, and Immunogenicity How AI supports biologic drug discovery, from designing molecules to predicting how easily they are made and whether the body attacks them. Talk Thu Oct 15 12:20 Title TBA Therapeutic peptide and GLP engineering Talk Thu Oct 15 12:20 Title TBA Analytics & Screening
University College Dublin Dublin, Ireland
	Talk Wed Oct 14 17:10 Selective Human Receptor Modulating Peptides for GPCR agonism and antagonism Protein Engineering Talk Thu Oct 15 12:00 New GLP-1R Biology: Agonists, Inverse Agonists & Beyond How ten peptides found by phage display turn on, turn down or otherwise change the GLP-1 receptor, and what that means for medicine.
IP Ironwood Pharmaceuticals Boston, MA
Large pharma Gastrointestinal health company that markets the peptide drug linaclotide.	Talk Thu Oct 15 11:40 Analytical Strategy for Therapeutic Synthetic Peptides: From Development to Quality Control How to plan the tests that check synthetic peptide drugs, from early development through routine quality control, in line with regulator expectations.
N Numaferm Düsseldorf, Germany
CDMO & CRO Biotech company producing peptides and proteins with its Numaswitch expression platform, including scarless GLP-1 analog manufacturing.	Talk Thu Oct 15 11:20 Disrupting Peptide Therapeutics: Numaferm’s Numaswitch Platform for Sustainable, Scalable, and Scarless GLP-1 Analog Manufacturing Therapeutic peptide and GLP engineering
OB Oncosimis Biotech
	Talk Thu Oct 15 12:40 Development of Novel Ultra-Long Acting GLP-1 Analogues for Diabetes and Obesity Therapeutic peptide and GLP engineering
Nuantic
nuantic.bio Software & AIStart-up AI-driven protein and peptide optimization, aiming to meet affinity and other goals with ten times fewer experimental variants, often in one round.	Booth Exhibiting at Booth S4
PT PEP-Therapy
Biotech Develops cell-penetrating peptide drugs that disrupt intracellular protein interactions, with oncology candidates in clinical development.	Booth Exhibiting (no floor booth listed)